RYI Insider Filing: Dividend Equivalent Accruals on RSU Awards
Rhea-AI Filing Summary
Molly D. Kannan, Chief Accounting Officer and Corporate Controller of Ryerson Holding Corp (RYI), reported acquisitions of dividend equivalent rights tied to restricted stock units (RSUs). Each RSU represents a contingent right to one share of RYI common stock. On 09/18/2025 she acquired dividend equivalent amounts of 16.613, 32.496 and 53.758 share equivalents, which increased her beneficial ownership in the underlying common stock to 2,074.819, 4,058.497 and 6,713.948 respectively. The accrued dividend equivalents relate to RSU grants from March 31, 2023, 2024 and 2025 and will vest on specified dates between March 31, 2026 and March 31, 2028 under the awards' original vesting schedules.
Positive
- Dividend equivalent rights accrued on existing RSUs, preserving the original award structure and vesting terms
- Vesting schedule disclosed with specific future vesting dates through March 31, 2028, showing clarity on timing of settlement
Negative
- None.
Insights
TL;DR: Routine insider accruals of dividend equivalents on RSUs reflect standard executive compensation vesting, not a material change to control.
The filing documents non-derivative accruals of dividend equivalent rights on previously granted restricted stock units for an executive officer. These accruals convert to one-for-one common share equivalents upon settlement and follow pre-existing vesting schedules through March 31, 2028. There is no indication of any out-of-cycle grants, accelerated vesting, or dispositions that would signal governance concerns. Impact on shareholder dilution is modest and tied to existing long-term incentive awards rather than new issuance.
TL;DR: Compensation accruals recorded as dividend equivalents increase reported beneficial holdings but align with standard RSU program mechanics.
The report breaks out dividend equivalent rights that accrued on RSUs from grants dated March 31 of 2023, 2024 and 2025. These amounts—16.613, 32.496 and 53.758 share equivalents—are modest in absolute terms and vest according to the original grant schedules. This is consistent with normal equity compensation accounting where dividends paid on common shares generate equivalent units for unvested awards. No cash transactions or option exercises are reported, and the reported price is $0, reflecting non-cash accruals rather than purchases.